DAPA may directly suppress the STAT3-YY1 signaling axis in CFs, leading to reduced CF proliferation and activation, decreased myocardial fibrosis, and improved cardiac insufficiency in DCM. The gene discussed is CFTR; the disease is Myocardial fibrosis.